Protagonist Therapeutics, Inc.
76.69-1.82 (-2.32%)
Oct 29, 4:00:00 PM EDT · NasdaqGM · PTGX · USD
Key Stats
Market Cap
4.77BP/E (TTM)
105.05Basic EPS (TTM)
0.73Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Protagonist Therapeutics posted a Q2 net loss of $34.8M, up 13.6% y/y from $30.6M, with diluted EPS at -$0.55 on 63.5M shares, while YTD net loss narrowed to $46.4M from $176.7M profit last year, driven by $33.9M collaboration revenue versus $259.1M (derived). Operating loss widened to $42.0M from $38.8M y/y as R&D expenses climbed 10.5% to $37.0M on clinical trials, yet interest income held steady at $7.4M. Cash swelled to $673M, fueling Phase 3 pushes for rusfertide in PV—NDA eyed Q4 2025—and icotrokinra's psoriasis approval pursuit. Operating cash flow hit $96.6M YTD, minus $1.4M capex for $95.2M FCF (derived). No debt burdens the balance sheet. Pipeline momentum builds steadily. Regulatory hurdles could delay approvals.
8-K
Q2 loss widens amid pipeline push
Protagonist Therapeutics reported Q2 2025 net loss of $34.8 million, up from $30.6 million last year, driven by higher R&D on new candidates PN-881 and PN-477, while revenue hit $5.5 million from Takeda services. Cash swelled to $673 million, funding operations through 2028. Key wins: icotrokinra NDA filed with FDA in July for psoriasis; rusfertide NDA on track for Q4. Pipeline advances, yet regulatory approvals remain uncertain.
8-K
Annual meeting results approved
Protagonist Therapeutics held its 2025 Annual Meeting on June 20, electing Harold E. Selick, Ph.D., and Bryan Giraudo as Class III directors with strong support—44.8 million for Selick, 42.5 million for Giraudo—despite some withheld votes. Stockholders approved executive compensation on an advisory basis, 50.8 million for versus 2.9 million against. They ratified Ernst & Young as auditors, 55.5 million in favor. Governance stays steady.
8-K
Q1 loss, strong cash, trial successes
Protagonist Therapeutics reported Q1 2025 financials, posting a $11.7 million net loss amid $28.3 million in collaboration revenue, while cash swelled to $697.9 million—enough runway through 2028. Positive Phase 3 VERIFY topline for rusfertide in polycythemia vera hit its endpoint, with full data set for ASCO plenary on June 1; icotrokinra's Phase 2b ANTHEM in ulcerative colitis also succeeded. Cash fuels pipeline push. These wins advance NDA filings by year-end.
10-Q
Q1 FY2025 results
Protagonist Therapeutics posted Q1 revenue of $28.3M from its Takeda collaboration, down sharply from $255.0M a year ago when the rusfertide license deal closed, yet up sequentially from Q4's $5.5M in development services. Operating expenses held steady at $47.6M, yielding an operating loss of $19.3M versus last year's $206.3M gain; net loss widened to $11.7M or $(0.19) per diluted share from $207.3M or $3.26 profit, with the gap to operating loss mainly from interest income offsetting R&D costs. Cash swelled to $697.9M including marketable securities, bolstered by $125.4M operating cash flow minus $94.4M investing outflows for a free cash flow of $30.9M (derived); no debt burdens the balance sheet. Positive Phase 3 data for rusfertide in PV and icotrokinra in psoriasis and UC fuel pipeline momentum. Competition in crowded immunology markets poses ongoing risks.
IPO
Employees
Sector
Industry
KALV
KalVista Pharmaceuticals, Inc.
10.96-0.17
LSTA
Lisata Therapeutics, Inc.
2.66-0.12
PKTX
ProtoKinetix, Inc.
0.01+0.00
PLRX
Pliant Therapeutics, Inc.
1.74-0.04
PPCB
Propanc Biopharma, Inc.
1.31-0.11
PRQR
ProQR Therapeutics N.V.
2.65-0.20
PTIX
Protagenic Therapeutics, Inc.
2.58-0.18
RAPT
RAPT Therapeutics, Inc.
29.78-0.35
VRTX
Vertex Pharmaceuticals Incorpor
417.21-5.18
VTVT
vTv Therapeutics Inc.
21.07+0.18